 |
97 Diseases |  |
239 Trials |
|
239 Trials |  |
14341 News |  |
| «12345678910111213...166167» |
- | rivaroxaban / Generic mfg.
Journal: Effective management of heparin-resistant thrombosis: a case study on rivaroxaban therapy guided by thromboelastography. (Pubmed Central) - Jun 1, 2024
No abstract available
- rivaroxaban / Generic mfg.
Effect of genetic variants on bleeding with rivaroxaban in pulmonary embolism patients: A multicenter prospective cohort study (Lehar 3) - May 31, 2024 - Abstract #ERS2024ERS_5354;
- | warfarin / Generic mfg.
Journal: Direct Comparison of the Effectiveness and Safety Among Direct Oral Anticoagulants and Warfarin in Japanese Patients: Nationwide Cohort Study in Japan. (Pubmed Central) - May 31, 2024
Dabigatran had lower usefulness than edoxaban and rivaroxaban in Japanese patients treated with NVAF, even after considering the unmeasured confounding factor of kidney function. Based on practical clinical data, edoxaban and rivaroxaban were the most useful anticoagulants in Japanese patients with NVAF.
- ||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Clinical guideline: Results of an International Survey of Opinions on the Definitions and Treatments for HIT: Communication from the ISTH SSC Subcommittee on Platelet Immunology. (Pubmed Central) - May 30, 2024
From n=102 survey responses, there was broad acceptance of rivaroxaban (74.5%) and apixaban (73.5%) even before platelet recovery; as well as for IVIg in the management of spontaneous (85.6%), persistent (83.7%) and treatment refractory HIT (87.4%). With this mandate for harmonizing terminologies and treatment approaches in special situations without robust clinical data owing to their rarity, we plan to conduct a robust survey, establish international consensus, and draft management guidelines for HIT and PF4-immune diseases in the near future.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Comparison of Different Direct Oral Anticoagulant Regimens in Atrial Fibrillation Patients with High Bleeding Risk. (Pubmed Central) - May 30, 2024
With this mandate for harmonizing terminologies and treatment approaches in special situations without robust clinical data owing to their rarity, we plan to conduct a robust survey, establish international consensus, and draft management guidelines for HIT and PF4-immune diseases in the near future. Among patients with a predominant bleeding risk but relatively low thrombosis risk, the low-dose DOAC regimen is not a more appropriate selection than standard-dose regimen.
- | rivaroxaban / Generic mfg.
Journal: Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban - IRIS. (Pubmed Central) - May 30, 2024
Among patients with a predominant bleeding risk but relatively low thrombosis risk, the low-dose DOAC regimen is not a more appropriate selection than standard-dose regimen. IRIS is the biggest real-life data registry regarding CA ablation on rivaroxaban in Italian setting, proving the safety and efficacy of rivaroxaban.
- | rivaroxaban / Generic mfg.
Journal: Ovarian vein thrombus in a pediatric patient: A case study. (Pubmed Central) - May 30, 2024
IRIS is the biggest real-life data registry regarding CA ablation on rivaroxaban in Italian setting, proving the safety and efficacy of rivaroxaban. She was discharged on rivaroxaban, which was discontinued after a 3
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials (Grand Ballroom West, 3rd Floor) - May 28, 2024 - Abstract #VEITH2024VEITH_413;
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
New Findings From The VOYAGER PAD And COMPASS RCTs With Low Dose Rivaroxaban (Xarelto [Janssen/J&J]) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open) (Grand Ballroom West, 3rd Floor) - May 28, 2024 - Abstract #VEITH2024VEITH_412;
- rivaroxaban / Generic mfg.
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN (Grand Ballroom West, 3rd Floor) - May 28, 2024 - Abstract #VEITH2024VEITH_409;
- ||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Journal, Adverse events: Patient concern regarding bleeding side effects from oral anticoagulation therapy for atrial fibrillation: An analysis from the multicenter KiCS-AF registry. (Pubmed Central) - May 27, 2024
She was discharged on rivaroxaban, which was discontinued after a 3 Approximately one-third of all patients with AF on anticoagulant therapy were concerned regarding bleeding from short- and long-term anticoagulant use.
- || Savaysa (edoxaban) / Daiichi Sankyo
Review, Journal: Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants. (Pubmed Central) - May 27, 2024
Information on the genetic effects is limited owing to the lack of large-scale studies. Uncovering the mechanisms of the genetic basis of sensitivity to DOACs helps in developing personalized therapy based on patient-specific genetic variants and improves the efficacy and safety of DOACs in the general population.
- | warfarin / Generic mfg.
Journal: Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Saudi Patients With Atrial Fibrillation. (Pubmed Central) - May 27, 2024
Overall, both DOACs and warfarin presented similar results regarding hemorrhagic complications when treating AF patients. However, the DOACs apixaban and rivaroxaban displayed higher risks of ischemic stroke compared to warfarin.
- | rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg., apixaban / Generic mfg.
Journal: Prophylaxis of Microvascular Thrombosis using Direct Oral Anticoagulants (DOAC) in Microvascular Free Tissue Transplantation - a Pilot Study. (Pubmed Central) - May 26, 2024
Based on our results in this pilot study, DOACs can be used with microvascular flaps. Further studies with larger sample sizes should be performed to find an optimal medication regimen both for patients already taking DOACs and perhaps even for those not taking DOACs.
- rivaroxaban / Generic mfg.
Distrupting Hypoxia-Induced Metabolic Adaptation in Oral Cavity Carcinoma Cells: Identifying the Potential of Rivaroxaban as an Anti-Coagulant Agent (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_510;
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal, Adherence: Role of a National Health Service Electronic Prescriptions Database in the Detection of Prescribing and Dispensing Issues and Adherence Evaluation of Direct Oral Anticoagulants. (Pubmed Central) - May 24, 2024
The total adherence level to DOAC therapy is evaluated as low and there was no significant difference in age, gender, or "switcher" status among adherence groups. Physicians' prescribing habits have changed over a decade.
- || rivaroxaban / Generic mfg.
Biomarker, Clinical, PK/PD data, Journal, PARP Biomarker: The Pharmacogenetic Variability Associated With the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study. (Pubmed Central) - May 23, 2024
This study found that that the regulation of the BRD3 gene might affect the PK and PD of rivaroxaban, suggesting that it should be studied as a new pharmacologic target. The correlation between this gene locus and clinical outcomes has yet to be verified in patients undergoing clinical treatment.
- | warfarin / Generic mfg.
Journal: Comparison of Direct Oral Anticoagulants and Warfarin in Chronic Limb-Threatening Ischemia. (Pubmed Central) - May 22, 2024
However, 1-year admissions for ISTH major bleeding were significantly higher among patients prescribed warfarin. A randomized trial may confirm these findings.
- | aspirin / Generic mfg.
Journal: Prevalence of risk factors for venous thromboembolism and aspirin resistance in Australian patients undergoing total hip and knee arthroplasty. (Pubmed Central) - May 22, 2024
Patients who received rivaroxaban had a greater average number of VTE risk factors. Guidelines should promote individualised prescribing in higher-risk patients.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Perioperative Management in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Minor Bleeding Risk Procedure: Rationale and Protocol for the PERIXa Study. (Pubmed Central) - May 22, 2024
P=N/A
For edoxaban or rivaroxaban, patients will withhold only a single dose on the procedure day...This study has the potential to generate evidence regarding the safety of perioperative management for patients, with AF undergoing procedures associated with minor bleeding risk. Clinicaltrials.gov: NCT05801068.
- || abelacimab (MAA868) / Anthos Therap, Novartis, MorphoSys, Lonza
Trial completion date: AZALEA-TIMI 71: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (clinicaltrials.gov) - May 20, 2024
P2, N=1200, Active, not recruiting, Sponsor: Anthos Therapeutics, Inc.
Clinicaltrials.gov: NCT05801068. Trial completion date: Jan 2025 --> Dec 2025
- || rivaroxaban / Generic mfg.
Clinical, Retrospective data, Journal: Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation. (Pubmed Central) - May 20, 2024
Trial completion date: Jan 2025 --> Dec 2025 Results from subgroup analyses of patients with age ?85, HAS-BLED score ?
- Savaysa (edoxaban) / Daiichi Sankyo
A comprehensive clinical case of recurrent venous thrombolism under therapeutic anticoagulation () - May 17, 2024 - Abstract #ISTH2024ISTH_2253;
Four weeks later, at the end of treatment, she presented with extensive pulmonary embolism (PE) requiring intensive care. Initial study of thrombophilia was negative and anticoagulant therapy was changed from LMWH (1mg/kg bid) to apixaban (5mg bid).
- rivaroxaban / Generic mfg.
Successful Treatment of Subarachnoid Hemorrhage using Prothrombin Complex Concentrate in Patient Taking Routine Oral Rivaroxaban () - May 17, 2024 - Abstract #ISTH2024ISTH_2244;
Bleeding in the central nervous system is considered life-threatening and should be treated promptly. In patients taking Rivaroxaban, specific antidote Andexanet alfa should be given.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
REDUCED DOSE OF RIVAROXABAN/APIXABAN Vs VITAMIN K ANTAGONISTS FOR SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM: A REAL-WORLD COMPARATIVE STUDY (110 A-C) - May 17, 2024 - Abstract #ISTH2024ISTH_2213;
In patients taking Rivaroxaban, specific antidote Andexanet alfa should be given. Among 798 patients (54.8% women, mean age 53.6
- rivaroxaban / Generic mfg., aspirin / Generic mfg., apixaban / Generic mfg.
Venous Thromboembolism Prophylaxis After Surgery For Hip Fracture: A Survey of Physician Practices from the HIPSTER study group. (111 A-C) - May 17, 2024 - Abstract #ISTH2024ISTH_2174;
172 (84%) indicated that an RCT is needed. Table 1 shows the participant characteristics, and Table 2 the current practices and preferences for an RCT.
- rivaroxaban / Generic mfg.
Effect of genetic variants on bleeding with rivaroxaban in pulmonary embolism patients: A multicenter prospective cohort study (Ballroom B3) - May 17, 2024 - Abstract #ISTH2024ISTH_2110;
The bleeding rate during extended treatment was 4.3%. Identified risk factors for bleeding included stroke, abnormal liver function, and hypertension.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Risk factors for Major Bleeding in Patients Anticoagulated with Factor Xa Inhibitors (FXai): An English Observational Study in the UK Clinical setting (AXIOM UK) (Ballroom B3) - May 17, 2024 - Abstract #ISTH2024ISTH_2108;
The most common indication was AF, followed by VTE, non-mechanical cardiac valve replacement and ACHD. There were 3,873 ISTH-defined MB.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
ST-Genesia Thromboscreen following use of a direct oral anticoagulant neutraliser correlates with VTE recurrence in patients on direct oral anticoagulants. (Ballroom B2) - May 17, 2024 - Abstract #ISTH2024ISTH_2107;
48.1% (n=125) proceeded to maintenance anticoagulation (MA) and were more likely to have had major and/or unprovoked VTE. Compared to patients with limited duration of anticoagulation (LD), the MA group showed higher endogenous thrombin potential (ETP) with (TM+, 783.9nM v 666.5nM.min, p=0.028) and without thrombomodulin (TM-, 1559.0nM v 1475.0nM, p=0.035) (Table 1), and a trend towards reduced ETP inhibition (49.6% v 55.4%, p=0.070).
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Reduced-Dose Direct Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism: Results from the GARFIELD-VTE Registry (Ballroom B2) - May 17, 2024 - Abstract #ISTH2024ISTH_2103;
P=N/A
In the reduced-dose group, 151 (46.3%) used apixaban and 175 (53.7%) rivaroxaban. Overall, subjects receiving reduced doses were older (p= < 0.001), and had lower median body mass index and platelet count (p=0.002 for both).
- rivaroxaban / Generic mfg.
Recurrent venous thromboembolism after anticoagulation discontinuation in patients with isolated distal deep vein thrombosis: A post-hoc analysis of the RIDTS trial (Ballroom B4) - May 17, 2024 - Abstract #ISTH2024ISTH_2067;
All recurrent events occurred after treatment of index IDDVT was completed, consisting of 47 (75.8%) recurrent IDDVTs and 15 (24.2%) proximal deep vein thromboses or pulmonary embolisms. Mean time from treatment discontinuation to recurrence was 7.4
- VMX-C001 / VarmX
A novel bleeding model in monkeys to assess efficacy of VMX-C001 for bypassing of FXa-DOAC anticoagulation (Ballroom B3) - May 17, 2024 - Abstract #ISTH2024ISTH_2061;
These increases were not associated with altered bleeding outcome post-injury (Fig 1). In animals pre-treated with rivaroxaban, PT and aPTT were prolonged (PT from 9.8
- Progression of anticoagulant-related nephropathy after initiating anticoagulant therapy (Ballroom B3) - May 17, 2024 - Abstract #ISTH2024ISTH_1967;
All patients required anticoagulant treatment for AF. Patients received apixaban 51 (40.4%), rivaroxaban 35 (27.8%), dabigatran 26 (20.6%) or warfarin 14 (11.2%) (Table 1).
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Rapid detection of FXa inhibitor activity using point of care testing (Plenary Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1952;
The anti-Xa levels were compared to the clotting time (CT) on RVV-test and there was a significant and positive correlation between the anti-Xa activity and CT. The Pearson correlation coefficient was 0.86 for apixaban, 0.84 for rivaroxaban and 0.84 for enoxaparin.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Preoperative DOAC Levels are Associated with Postoperative Bleeding and Effects are Mediated by Thrombin Generation Parameters - [SONAR]: A Nested Case-Control Study and Causal Mediation Analysis (Plenary Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1951;
DOAC levels were higher among cases compared to controls (p = 0.03). Stronger correlations between TGA parameters and residual DOAC levels were observed in cases compared to controls (Figure 1).
- rivaroxaban / Generic mfg., cyclophosphamide / Generic mfg., azathioprine / Generic mfg.
Unusual thromboses revealing a multisystemic granulomatosis (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1947;
Imaging revealed a dysmorphic liver, thrombosis of the suprahepatic veins, mediastinal adenopathy with diffuse lymphadenopathy. The diagnosis of Multisystemic Sarcoidosis was established based on mediastino-pulmonary involvement, granulomas in bronchial, hepatic, bone, and accessory salivary gland biopsies without signs of necrosis or malignancy.
- Savaysa (edoxaban) / Daiichi Sankyo
Safety and efficacy of DOACs in cirrhotic and non-cirrhotic splanchnic vein thrombosis: preliminary results from prospective observational study. (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1939;
Of 27 patients with chronic SVT, 19 (70%) had a cavernoma. 50% of patients received rivaroxaban, 44% apixaban, 2% dabigatran, and 4% edoxaban.
- rivaroxaban / Generic mfg.
The Role of Rivaroxaban in cancer-associated venous thromboembolism prevention in outpatients setting: a systematic review (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1929;
Rivaroxaban is associated with a reduced risk of recurrent VTE compared to LMWH without a significant impact on composite outcomes, major bleeding, or all-cause mortality. These findings support the use of rivaroxaban as reasonable alternatives to LMWHs for the treatment of CAT when used in accordance with guidelines.
- rivaroxaban / Generic mfg., aspirin / Generic mfg., enoxaparin sodium / Generic mfg.
Platelet-tumor cell interaction is mediated by fibrin mesh, which opens a possibility for reduction of metastasis by late-stage anticoagulation (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1921;
MCF-7 and SH-SY5Y cells also induced platelet aggregation, but with increased lag-time (2-fold for MCF-7 and 5-fold for SH-SY5Y). The time of aggregation anti-correlated with PFP fraction or tumor cell concentration.
- aspirin / Generic mfg.
Primary deep vein thrombosis prophylaxis in high-risk ambulatory multiple myeloma patients: DOACs or vitamin K antagonists are better than aspirin or no prophylaxis (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1904;
54 MM patients were evaluated. 38 (70%) received thromboprophylaxis and 16 didn
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Title: "Vascular Enigma Unveiled: Navigating the Intricacies of a 41-Year-Old's Complex Vascular Odyssey" (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1839;
The subsequent genetic analysis revealed a heterozygous PAI-I mutation and elevated homocysteine levels, contributing to the overall complexity of the case. Conclusion(s) : This case report emphasizes the challenges in managing a 41-year-old female with intricate vascular manifestations, encompassing hemangiomas, deep vein thrombosis, and genetic mutations.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Investigation of the reversal potential of engineered Factor Xa agents in apixaban and rivaroxaban treated plasma (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1645;
In the presence of high concentrations of apixaban, andexanet alfa, unlike the FXa-variants, does not reverse the DOAC-induced inhibition of FXa activity. Conclusion(s) : FXa variants designed and evaluated by us in this study can evade apixaban and rivaroxaban induced inactivation of FXa.
- Prothromplex (prothrombin complex) / Takeda
A phase 3 trial of TAK-330 (4-factor prothrombin complex concentrate [4F-PCC]) vs standard-of-care 4F-PCCs for FXa inhibitor-induced anticoagulation reversal before urgent surgery/invasive procedure (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1611;
P3
Not applicable. Conclusion(s) : Results from this study will provide efficacy and safety data on TAK-330 versus standard-of-care 4F-PCCs for the reversal of direct oral FXa inhibitor-induced anticoagulation in patients requiring urgent surgery/invasive procedures.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Estimate of 2024 Preventable Deaths in US Patients Treated with Apixaban and Rivaroxaban Requiring Reversal for Major Bleeding Events (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1561;
Given a fixed annual increase of 25%, major bleeds from FXaI requiring hospitalization will rise to 125,826, 157,282, 196,603, and 245,753 in 2021 through 2024. Assuming 80% (196,602 patients) require bleed management and 75% of these will be given 4F-PCC yields 147,452 patients.
- Savaysa (edoxaban) / Daiichi Sankyo
Outcomes of Bleeding in Patients with Myeloproliferative Neoplasms Treated with Direct Oral Anticoagulants (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1554;
Concomitant therapies included antiplatelet agents (34.5%) and cytoreductive drugs (56.3%), with hydroxyurea accounting for 76.1% of the cytoreductive therapies. Compared to the VTE group, the AF group was statistically significantly older (p = 0.010) and had a higher proportion of patients with elevated CHA2DS2-VASc scores (p = 0.021).
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Evaluating a "universal" calibrator for anti-Xa testing in patients taking rivaroxaban and apixaban (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1548;
Linear regression demonstrated significant correlation at site 1, R2 0.99, p< 0.001. Quadratic models best defined correlations at sites 2 (R2 0.93, P< 0.001) and 3 (R2 0.94, P< 0.001).
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
The Incidence of Major Bleeding and Case Fatality Rates in Patients Anticoagulated with Factor Xa Inhibitors: An Observational Study in the UK Clinical Setting (AXIOM UK) (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1547;
The most common FXai indication was AF (72%). There were 10,163 patients (4.2%) hospitalised for bleeding events during FXai use.
- rivaroxaban / Generic mfg.
Venous Thrombosis Secondary to Vitamin B12 Deficiency may not be solely explained by hyperhomocysteinemia: about 10 Cases (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1543;
Median age of 42 years (27-72). Two had history of miscarriages, and one patient was using oral contraceptives.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Antiphospholipid syndrome in adult male patients in Mexico. (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1536;
Results of 66 patients (40 and 26 with primary and secondary APS, respectively), with a median age of 26.5 years-old (range: 16-57), were analyzed. Diseases associated with secondary APS included: SLE (n=9), RA (n=7), Sj
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
The efficacy and safety of direct oral anticoagulants (DOACs) in the secondary prevention of VTE in individuals with inherited antithrombin deficiency: a cohort study from a tertiary referral centre (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1525;
There were no VTE recurrences on standard dose DOAC, except in a noncompliant patient receiving dabigatran. There was one reported thrombosis recurrence with compliant DOAC use